Kanwal Raghav

Jul 30, 2024 | nature.com | Sarina Piha-Paul |Vivek Subbiah |Aung Naing |Jaffer Ajani |Kanwal Raghav |Gordon Mills | +3 more

AbstractCancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2.

Jun 23, 2023 | onclive.com | Kanwal Raghav

Kanwal P. S. Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, medical director, Division of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center, discusses the rationale behind the phase 2 DESTINY-CRC02 trial (NCT04744831) evaluating fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.

Jun 4, 2023 | onclive.com | Kanwal Raghav

Kanwal P. S. Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, medical director, Division of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center, discusses primary findings from the phase 2 DESTINY-CRC02 trial (NCT04744831) of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with metastatic colorectal cancer with HER2 amplification or overexpression.